Arbutus Biopharma Corporation Forecast, price target & analysts
Arbutus Biopharma Corporation Target price 2026 - Analyst rating & recommendation
Arbutus Biopharma Corporation Classifications & Recommendation
Arbutus Biopharma Corporation Price Target
| Target Price | $5.61 |
| Price | $4.85 |
| Potential |
15.67%
register free of charge
|
| Number of Estimates | 3 |
|
3 Analysts have issued a price target Arbutus Biopharma Corporation 2027 .
The average Arbutus Biopharma Corporation target price is $5.61.
This is
15.67%
register free of charge
$5.78
19.07%
register free of charge
$5.56
14.54%
register free of charge
|
|
| A rating was issued by 7 analysts: 6 Analysts recommend Arbutus Biopharma Corporation to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Arbutus Biopharma Corporation stock has an average upside potential 2027 of
15.67%
register free of charge
|
Sales and Margin forecast 2026, 2027 & 2028
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 14.08 | 185.84 |
| 128.20% | 1,219.89% | |
| Net Margin | -237.93% | 80.27% |
| 79.00% | 133.74% |
3 Analysts have issued a sales forecast Arbutus Biopharma Corporation 2026 . The average Arbutus Biopharma Corporation sales estimate is
This results in the following potential growth metrics:
3 Arbutus Biopharma Corporation Analysts have issued a net profit forecast 2026. The average Arbutus Biopharma Corporation net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 & 2028
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.17 | 0.75 |
| 55.26% | 541.18% | |
| P/E | 6.43 | |
| EV/Sales | 4.69 |
3 Analysts have issued a Arbutus Biopharma Corporation forecast for earnings per share. The average Arbutus Biopharma Corporation EPS is
This results in the following potential growth metrics and future valuations:
Arbutus Biopharma Corporation...
Current Arbutus Biopharma Corporation Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Chardan Capital |
Locked
➜
Locked
|
Locked | Nov 14 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Aug 11 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Mar 28 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 21 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Nov 20 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 18 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 07 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Nov 14 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Aug 11 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Mar 28 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 21 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Nov 20 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 18 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 07 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
